Showing 14,021 - 14,040 results of 21,342 for search '(( significantly ((greatest decrease) OR (nn decrease)) ) OR ( significant decrease decrease ))', query time: 0.55s Refine Results
  1. 14021

    Forest plot for TNF- by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  2. 14022
  3. 14023

    Demographical features of the sample. by Aymee Lobato Brito (19812790)

    Published 2024
    “…</p><p>Results</p><p>The evaluated parameters showed significantly different values between the groups, where the Leprosy group exhibited significantly higher values compared to the control group, both in the OE and CE conditions for all four parameters. …”
  4. 14024

    The impact of excessive DNA amounts used for bisulfite conversion on the amplification efficiency and the methylation level of <i>LINE-1</i> and <i>Alu</i>. by Trang Thi Quynh Tran (20485595)

    Published 2024
    “…A serial dilution of human methylated DNA amounts, corresponding to 500 ng, 50 ng, 5 ng, 1 ng and 0.5 ng was treated by bisulfite. The ΔCT values significantly differ at input amounts from 500 ng to 0.5 ng. …”
  5. 14025

    Correlation description. by Aymee Lobato Brito (19812790)

    Published 2024
    “…</p><p>Results</p><p>The evaluated parameters showed significantly different values between the groups, where the Leprosy group exhibited significantly higher values compared to the control group, both in the OE and CE conditions for all four parameters. …”
  6. 14026

    Kinetics of differential gene expression after rapid degradation of endogenous OGT in MEFs. by Sara Formichetti (20536052)

    Published 2025
    “…Note that <i>OsTIR1</i> is also significantly downregulated after auxin addition, suggesting that an unknown mechanism counteracts the degron system upon auxin treatment. …”
  7. 14027

    Image 4_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

    Published 2024
    “…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
  8. 14028

    Table 1_Variations in vitamin D status among Chinese children aged 1–6 years during the COVID-19 pandemic.xlsx by Yongfeng Qiao (3354326)

    Published 2025
    “…The average of 25(OH)D concentration were 38.2 ± 9.8 ng/ml, significantly varying by age and season. 25(OH)D concentrations decreased with age, from 42.3 ± 8.8 ng/ml at 1-year-olds to 37.4 ± 8.2 ng/ml at 2-year-olds, and further to 30.2 ± 8.1 ng/ml at 3 to 6-year-olds. …”
  9. 14029

    Image 2_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

    Published 2024
    “…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
  10. 14030

    Image 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

    Published 2024
    “…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
  11. 14031

    Effect of management activities on forest soil properties in the Rocky Mountains: II. Tree, stump, and downed woody debris data by Theresa B. Jain (10288169)

    Published 2025
    “…The specific purpose of the tree, stump, and downed woody debris study was to describe whether the growth of trees, and the amount of stumps or dead woody materials varied significantly on a site if it was dozer piled, prescribe burned, or in an unharvested area. …”
  12. 14032

    Image 5_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

    Published 2024
    “…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
  13. 14033

    Table 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.docx by Xiao Li (107004)

    Published 2024
    “…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
  14. 14034

    Image 3_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg by Xiao Li (107004)

    Published 2024
    “…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
  15. 14035

    Western blot antibody information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  16. 14036

    Information on healthy and aniridia subjects. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  17. 14037

    qPCR primers information. by Shuailin Li (11907158)

    Published 2025
    “…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
  18. 14038

    Bias risk assessment of included studies. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  19. 14039

    Forest plot for hs-CRP. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”
  20. 14040

    Forest plot for IL-6. by Xuqin Du (8803772)

    Published 2025
    “…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”